Browse studies

Find your next paid study

27,352 recruiting studies available now

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Crohn's Disease or Ulcerative Colitis

This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells f…

Inflammatory Bowel Diseases

Estimated

~$150 – $3,000

Actual pay is set by the research site.

The Foundation for Orthopaedics and Regenerative MedicineNCT05003947

Phase 1

A Phase 1/2 Clinical Study to Evaluate the Optimal Dose and the Protective Effect of CMV-MVA Triplex Vaccine in Pediatric Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant

This phase I/II trial studies the side effects and best dose of multi-antigen cytomegalovirus (CMV)-modified vaccinia ankara vaccine and to see how well it wor…

Cytomegaloviral InfectionHematopoietic Cell Transplant Recipient

Estimated

~$150 – $3,000

Actual pay is set by the research site.

City of Hope Medical CenterNCT03354728

Phase 4

Comparative Effectiveness of Available Treatments for Sinus and Ear Infections in Children (Acute Otitis Media)

This study is being conducted at multiple hospitals and clinics to better understand whether antibiotics truly help children feel better when they have an ear …

Acute Otitis Media (AOM)

Estimated

~$25 – $1,500

Actual pay is set by the research site.

Nader ShaikhNCT07730814

Observational

A Pilot Study Assessing the Safety and Efficacy of Histotripsy as an Adjunctive Treatment for Biliary Tract Cancer

The purpose of this pilot study is to examine the safety and feasibility of histotripsy in two cohorts of 12 patients each with Biliary Track Cancer (BTC), wit…

Biliary Track Cancer

Estimated

~$10 – $1,125

Actual pay is set by the research site.

NYU Langone HealthNCT07853690

Phase 1

A Phase 1a/1b Study of the Selective Tyrosine Kinase Inhibitor NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

Phase 1a/1b dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-330, determine the recommended Phase 2 dose (RP2D), and…

Locally Advanced Solid TumorMetastatic Solid Tumor

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Nuvalent Inc.NCT06521554

Observational

Preventing Financial Adversity Among Early-Stage Cancer Patients Through Unrestricted Cash (PAYMENT) Pilot Study

This clinical trial studies whether an unrestricted cash payment program can be used to improve financial and clinical outcomes in early-stage cancer patients …

Malignant Solid Neoplasm

Estimated

~$10 – $750

Actual pay is set by the research site.

Fred Hutchinson Cancer CenterNCT06771739

Phase 3

Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma

This is a trial to compare neurocognitive outcomes in the intent-to-treat population 2.5 years after diagnosis between patients with newly diagnosed, non-metas…

Medulloblastoma

Estimated

~$50 – $1,500

Actual pay is set by the research site.

Nationwide Children's HospitalNCT07291102

Phase 2

Optimizing Antibody-Drug Conjugate Therapy Through Molecular Analysis for Therapy Choice (ADC MATCH)

This phase II ADC MATCH screening and multi-sub-study treatment trial is evaluating whether biomarker-directed treatment with one of three antibody-drug conjug…

Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm

Estimated

~$75 – $1,800

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT06311214

Phase 1

A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma

Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced u…

Ovarian CancerPancreas CancerUrothelial Carcinoma+6 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Nammi Therapeutics IncNCT06582017

Phase 2

A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surovatamig in Adults With Antibody-mediated Kidney Disease

The purpose of this study is to assess the safety, tolerability, pharmacokinetic, and efficacy of surovatamig administered by subcutaneous injection in adult p…

Primary Membranous Nephropathy

Estimated

~$75 – $3,000

Actual pay is set by the research site.

AstraZenecaNCT07571746

Phase 3

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Period and Long-term Extension to Assess the Efficacy and Safety of Rilzabrutinib in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)

This is a parallel-group, Phase 3, double-blind, 2-arm study to investigate the efficacy, safety, PK and PD of oral rilzabrutinib in achieving durable Hb respo…

Autoimmune Haemolytic Anaemia

Estimated

~$50 – $2,250

Actual pay is set by the research site.

SanofiNCT07086976

Phase 1

Phase 1b Study of Teclistamab in Relapsed/Refractory Plasmablastic Lymphoma

This phase Ib trial tests the safety, side effects, and best dose of teclistamab in treating patients with plasmablastic lymphoma that has come back after a pe…

Recurrent Plasmablastic LymphomaRefractory Plasmablastic Lymphoma

Estimated

~$150 – $2,700

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT07332507